View source for Breakthrough discovery associated with Roblitinib FGF401 as being a ReversibleCovalent Inhibitor from the Kinase Action of Fibroblast Development Aspect Receptor 4
From EECH Central
You do not have permission to edit this page, for the following reasons:
You can view and copy the source of this page.